Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 5.88mg equivalent to estradiol 5.69 mg (75µg/24h) - transdermal patch - 75 mcg/24h - active: estradiol hemihydrate 5.88mg equivalent to estradiol 5.69 mg (75µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

hospira nz ltd - estradiol 2mg equivalent to 25 µg/24h - transdermal patch - 2 mg(25mcg / 24h) - active: estradiol 2mg equivalent to 25 µg/24h excipient: acrylic copolymer, durotak 326-1753 acrylic copolymer, durotak 387-2287

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - estradiol 4.33mg equivalent to 50 µg/24h oestradiol; estradiol hemihydrate 0.62mg equivalent to oestradiol 50 µg/24 hours;  ; norethisterone acetate 2.7mg equivalent to norethisterone acetate 140 µg/24 hours;   - transdermal patch - 50 + 50/140 - active: estradiol 4.33mg equivalent to 50 µg/24h oestradiol excipient: 1,3-butylene glycol acrylic adhesive bentonite dipropylene glycol ethylenevinylacetate copolymer lecithin liquid paraffin oleic acid polyisobutylene synthetic adhesive active: estradiol hemihydrate 0.62mg equivalent to oestradiol 50 µg/24 hours   norethisterone acetate 2.7mg equivalent to norethisterone acetate 140 µg/24 hours   excipient: acrylic adhesive dipropylene glycol oleic acid povidone silicone adhesive

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - estradiol 0.312 mg/cm² equivalent to 25 µg/24h;   - transdermal patch - 25 mcg/24h - active: estradiol 0.312 mg/cm² equivalent to 25 µg/24h   excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

viatris limited - estradiol hemihydrate 1.64mg;   - transdermal patch - 100 mcg/24h - active: estradiol hemihydrate 1.64mg   excipient: acrylic adhesive dipropylene glycol oleyl alcohol pegoterate polyolefin povidone silicone adhesive - estradiol is indicated for the following: - oestrogen replacement therapy for the treatment of the symptoms of natural or surgically induced menopause. - prevention of postmenopausal osteoporosis.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

viatris limited - estradiol hemihydrate 0.41mg;   - transdermal patch - 25 mcg/24h - active: estradiol hemihydrate 0.41mg   excipient: acrylic adhesive dipropylene glycol oleyl alcohol pegoterate polyolefin povidone silicone adhesive - estradiol is indicated for the following: - oestrogen replacement therapy for the treatment of the symptoms of natural or surgically induced menopause. - prevention of postmenopausal osteoporosis.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

viatris limited - estradiol hemihydrate 0.82mg;   - transdermal patch - 50 mcg/24h - active: estradiol hemihydrate 0.82mg   excipient: acrylic adhesive dipropylene glycol oleyl alcohol pegoterate polyolefin povidone silicone adhesive - estradiol is indicated for the following: - oestrogen replacement therapy for the treatment of the symptoms of natural or surgically induced menopause. - prevention of postmenopausal osteoporosis.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

viatris limited - estradiol hemihydrate 1.23mg;   - transdermal patch - 75 mcg/24h - active: estradiol hemihydrate 1.23mg   excipient: acrylic adhesive dipropylene glycol oleyl alcohol pegoterate polyolefin povidone silicone adhesive - estradiol is indicated for the following: - oestrogen replacement therapy for the treatment of the symptoms of natural or surgically induced menopause. - prevention of postmenopausal osteoporosis.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 2.04mg equivalent to estradiol 1.97 mg (25 µg/24h) - transdermal patch - 25 mcg/24h - active: estradiol hemihydrate 2.04mg equivalent to estradiol 1.97 mg (25 µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

kaiser foundation hospitals - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.5 mg - estradiol tablets usp are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). - prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology , clinical studies .) the mainstays for decreasing the risk of postmenop